Intensive Care MedicineNCT06912204
Predictive Value of the mNutric Score and Survival Analysis in Critically Ill Patients Hospitalised in the Intensive Care Unit
An observational study of Intensive Care Medicine, run by Amasya University at 1 site in Turkey (Türkiye).
Trial summary
Our study is an observational study and the follow-up hematological tests of patients in the intensive care unit will be recorded during their first admission. In this study, routinely checked blood parameters in patients will be interpreted and mnutric scores created together with their clinical features will be… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Intensive Care Medicine
- How many people
- 85 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Nov 2024to 15 Mar 2025
- How long will I take part?
- 28 Days
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Critical care patients admitted to the intensive care unit and no deaths within 24 hours
Who may be able to join
- over 18 years old , Patients who have been hospitalized for more than 24 hours
Who cannot join
- under 18 years old, pregnancy patients, Patients hospitalized for less than 24 hours
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Amasya University Training and Research Hospital
Samsun, 55200
About this study
Our study is an observational study and the follow-up hematological tests of patients in the intensive care unit will be recorded during their first admission. In this study, routinely checked blood parameters in patients will be interpreted and mnutric scores created together with their clinical features will be recorded. Routine blood tests will be performed during these records and no intervention will be made. Only an observational study will be conducted.
Read the detailed description
Written informed consent was obtained from all participants or participants whose signature could not be obtained and included in the study. Between 1 December 2024 and 1 April 2025, 85 critically ill patients admitted to the anaesthesia intensive care unit of our hospital were included in the study. Patients aged 18 years and older who were admitted to the ICU and followed for more than 24 hours were included in the study. Patients younger than 18 years, pregnant women and patients with gastrointestinal motility disorders were excluded from the study. Patients' demographic characteristics, including age, sex, and comorbidities, were recorded at the time of initial admission. Haemoglobin (Hb), white blood cell (WBC), lymphocyte, platelet, aspartate aminotransferase (AST), alanine aminotransferase (ALT), C-reactive protein (CRP) and albumin levels were recorded during the first hospitalisation. Sequential Organ Failure Assessment Score 2 (SOFA 2) and Apache 2 score values were recorded. The 28-day follow-up of these patients was recorded. Patients who died within 28 days and patients who survived were grouped as survivors. The use of vasoactive drugs, renal replacement therapy, the need for mechanical ventilation and the length of stay in the intensive care unit of the groups were recorded during the follow-up period. The nutrition team placed a nasogastric catheter in all patients and started enteral nutrition at 25-30 kcal/kg in patients without contraindications.
- Conditions
- Intensive Care Medicine
- Keywords
- mturtic score, intensiva care, mortality
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| survived | Not described | |
| non-survived | Patients who did not survive after 28 days |
What is being measured
The primary outcome is the main question the study is designed to answer.
primer
It was aimed to investigate the mnutric scores of patients who survived and did not survive after 28 days of follow-up.
Measured: 28-day follow-up period
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Apr 2025
- Study start1 Nov 2024
- Primary completion1 Mar 2025
- Study completion15 Mar 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Intensive Care MedicineStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 85 participants (actual)
- Target duration
- 28 Days
Sponsor and investigators
- Lead sponsor
- Amasya University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Harun Tolga Duran, Amasya University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06912204
- Sponsor's protocol ID
- htd
- Status last verified
- Jun 2025
- First submitted
- 29 Mar 2025
- Last updated
- 15 Jun 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: patient outcome data
Publications
Grillo-Ardila CF, Tibavizco-Palacios D, Triana LC, Rugeles SJ, Vallejo-Ortega MT, Calderon-Franco CH, Ramirez-Mosquera JJ. Early Enteral Nutrition (within 48 h) for Patients with Sepsis or Septic Shock: A Systematic Review and Meta-Analysis. Nutrients. 2024 May 22;16(11):1560. doi: 10.3390/nu16111560.
PubMed 38892494
Study at a glance
From the registry record, last updated by the sponsor on 15 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Predictive Value of the mNutric Score and Survival Analysis in Critically Ill Patients Hospitalised in the Intensive Care Unit
- ClinicalTrials.gov ID
- NCT06912204
- Acronym / sponsor ID
- htd
- Conditions
- Intensive Care Medicine
- Keywords
- mturtic score, intensiva care, mortality
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 85 participants (actual)
- Lead sponsor
- Amasya UniversityUniversity, hospital or other
- Study start
- 1 Nov 2024 (actual)
- Primary completion
- 1 Mar 2025 (actual)
- Study completion
- 15 Mar 2025 (actual)
- First posted
- 4 Apr 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Our study is an observational study and the follow-up hematological tests of patients in the intensive care unit will be recorded during their first admission. In this study, routinely checked blood parameters in patients will be interpreted and mnutric scores created together with their clinical features will be recorded. Routine blood tests will be performed during these records and no intervention will be made. Only an observational study will be conducted.
Detailed description
Written informed consent was obtained from all participants or participants whose signature could not be obtained and included in the study. Between 1 December 2024 and 1 April 2025, 85 critically ill patients admitted to the anaesthesia intensive care unit of our hospital were included in the study. Patients aged 18 years and older who were admitted to the ICU and followed for more than 24 hours were included in the study. Patients younger than 18 years, pregnant women and patients with gastrointestinal motility disorders were excluded from the study. Patients' demographic characteristics, including age, sex, and comorbidities, were recorded at the time of initial admission. Haemoglobin (Hb), white blood cell (WBC), lymphocyte, platelet, aspartate aminotransferase (AST), alanine aminotransferase (ALT), C-reactive protein (CRP) and albumin levels were recorded during the first hospitalisation. Sequential Organ Failure Assessment Score 2 (SOFA 2) and Apache 2 score values were recorded. The 28-day follow-up of these patients was recorded. Patients who died within 28 days and patients who survived were grouped as survivors. The use of vasoactive drugs, renal replacement therapy, the need for mechanical ventilation and the length of stay in the intensive care unit of the groups were recorded during the follow-up period. The nutrition team placed a nasogastric catheter in all patients and started enteral nutrition at 25-30 kcal/kg in patients without contraindications.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Target follow-up
- 28 Days
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| survived | – | – |
| non-survived | – | –Patients who did not survive after 28 days |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Critical care patients admitted to the intensive care unit and no deaths within 24 hours
Key inclusion criteria (1 listed)
- over 18 years old , Patients who have been hospitalized for more than 24 hours
Key exclusion criteria (1 listed)
- under 18 years old, pregnancy patients, Patients hospitalized for less than 24 hours
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
primer
Time frame: 28-day follow-up period
It was aimed to investigate the mnutric scores of patients who survived and did not survive after 28 days of follow-up.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Jun 2025.
- Background: PubMed 38892494Grillo-Ardila CF, Tibavizco-Palacios D, Triana LC, Rugeles SJ, Vallejo-Ortega MT, Calderon-Franco CH, Ramirez-Mosquera JJ. Early Enteral Nutrition (within 48 h) for Patients with Sepsis or Septic Shock: A Systematic Review and Meta-Analysis. Nutrients. 2024 May 22;16(11):1560. doi: 10.3390/nu16111560.
- Individual participant dataSharing planned: Yes. patient outcome data
Related trials for Intensive Care Medicine
Not yet recruitingObservational study
Core Competencies in General Intensive Care Ultrasound (GenIUS): a Delphi Study
Critical Illness, Ultrasound
Active, not recruiting
The MOUD Plus Pilot: Counseling and Peer Support to Support Retention for Medically Complex Patients With Opioid Use Disorder Seen In Primary Care
Opioid Dependence, Substance Abuse Disorders
Recruiting
Immediate Versus Substantiated Antibiotic Therapy in Suspected Non-Severe Ventilator-Associated Pneumonia
Ventilator-Associated Pneumonia (VAP)
RecruitingObservational study
Microbiome and Enteric Signatures in Sepsis-associated Hepatorenal Injury
Sepsis, Acute Kidney Injury Due to Sepsis
RecruitingObservational study
B Lymphocyte Populations in the Pulmonary Microenvironment of Patients Under Mechanical Ventilation With or Without VAP (Ventilator-Associated Pneumonia)
Ventilator-associated Pneumonia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Intensive Care Medicine, run by Amasya University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
primer (time frame: 28-day follow-up period). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06912204, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jun 2025.